Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arch Biopartners Inc
V.ARCH
Alternate Symbol(s):
ACHFF
Technology
Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is...
LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
TSXV:ARCH - Post Discussion
Arch Biopartners Inc
> Todays House Positions
New Post
View:
Discussion
List
(9)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Dec 30, 2021 4:25pm
Todays House Positions
House Positions for C:ARCH from 20211230 to 20211230
House
Bought
$Val
Ave
Sold
$Val
Ave
Net
$Net
22 Fidelity
57,330
202,949
3.54
0
57,330
-202,949
9 BMO Nesbitt
20,000
69,615
3.481
0
20,000
-69,615
7 TD Sec
15,288
56,203
3.676
3,140
11,276
3.591
12,148
-44,927
13 Instinet
9,200
32,676
3.552
300
1,050
3.50
8,900
-31,626
53 Morgan Stanley
8,000
31,440
3.93
0
8,000
-31,440
85 Scotia
3,194
11,132
3.485
0
3,194
-11,132
83 Mackie
1,000
3,445
3.445
0
1,000
-3,445
68 Leede
680
2,357
3.466
454
1,658
3.652
226
-699
19 Desjardins
5
17
3.40
0
5
-17
72 Credit Suisse
0
300
1,158
3.86
-300
1,158
18 Echelon
0
400
1,396
3.49
-400
1,396
2 RBC
1,601
5,842
3.649
2,695
9,639
3.577
-1,094
3,797
80 National Bank
1,821
6,292
3.455
3,453
12,218
3.538
-1,632
5,926
39 Merrill Lynch
0
2,105
7,513
3.569
-2,105
7,513
79 CIBC
17,600
62,699
3.562
25,700
91,330
3.554
-8,100
28,631
14 ITG
667
2,324
3.484
17,054
59,716
3.502
-16,387
57,392
1 Anonymous
45,115
161,410
3.578
125,900
451,450
3.586
-80,785
290,040
TOTAL
181,501
648,401
3.572
181,501
648,404
3.572
0
3
(180)
•••
stocksarefun
X
View Profile
View Bullboard History
Comment by
stocksarefun
on Dec 30, 2021 5:37pm
So.. net -80k shares for anonymous today alone. Endless shares???
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Major Funding Secured! Company Closes First Round of Private Placement
This $10M Deal Could Reshape the Future of Global Creator Platforms
New Gold and Copper Hotspot Identified – What’s Next for This Serbian Project?